Updates are available Correction dated 2024-03-14
Click to view Correction: https://doi.org/10.1186/s12967-024-04998-y
-
Authors
Horny, Kai
Sproll, Christoph
Peiffer, Lukas
Furtmann, Frauke
Gerhardt, Patricia
Gravemeyer, Jan
Stoecklein, Nikolas H.
Spassova, Ivelina
Becker, Jürgen C. http://orcid.org/0000-0001-9183-653X
-
Funding
Funding for this research was provided by:
Deutschen Konsortium für Translationale Krebsforschung (OE 0460 ED003)
Bundesministerium für Bildung und Forschung (03VP01062)
Deutsches Krebsforschungszentrum (DKFZ)
- License Information
-
More Information
Article History
Received: 27 October 2022
Accepted: 1 April 2023
First Online: 19 April 2023
Change Date: 14 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12967-024-04998-y
Declarations
:
: Written informed consent was obtained from each patient and the Ethics Committee of the Medical Faculty of the Heinrich-Heine-University Düsseldorf (#3090) approved the study. All procedures involving human participants are in accordance with the ethical standards of the institutional and research committee and with the Helsinki Declaration.
: Not applicable.
: JCB is receiving speaker’s bureau honoraria from Amgen, Pfizer, MerckSerono, Recordati and Sanofi, is a paid consultant/advisory board member/DSMB member for Boehringer Ingelheim, InProTher, MerckSerono, Pfizer, 4SC, and Sanofi/Regeneron. His group receives research grants from Bristol-Myers Squibb, Merck Serono, HTG, IQVIA, and Alcedis. None of these activities are related to the present manuscript. The other authors including KH, CS, LP, FF, PG, JG, NS, IS declare no competing of interests.
